Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates.
about
Identification of a functional receptor for granulocyte colony-stimulating factor on plateletsNew developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastimConcise review: Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilizationTherapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation.A lethal myeloproliferative syndrome in mice transplanted with bone marrow cells infected with a retrovirus expressing granulocyte-macrophage colony stimulating factor.Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitorsEnhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferonGranulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis.Hochuekkito, a Kampo (Traditional Japanese Herbal) Medicine, and its Polysaccharide Portion Stimulate G-CSF Secretion from Intestinal Epithelial CellsPharmaceutical intervention in the JAK/STAT signaling pathway.Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trialComparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trialEffects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment of cynomolgus primatesThe kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo.Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice.Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.Long-term exposure to retrovirally expressed granulocyte-colony-stimulating factor induces a nonneoplastic granulocytic and progenitor cell hyperplasia without tissue damage in miceSynergistic myelopoietic actions in vivo after administration to mice of combinations of purified natural murine colony-stimulating factor 1, recombinant murine interleukin 3, and recombinant murine granulocyte/macrophage colony-stimulating factor.Nuclear phospholipid scramblase 1 prolongs the mitotic expansion of granulocyte precursors during G-CSF-induced granulopoiesisRole of lipegfilgrastim in the management of chemotherapy-induced neutropeniaClinical applications of granulocyte colony stimulating factor (G-CSF).Granulocyte-colony stimulating factor levels in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosisRetinoids in cancer treatment.Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.The potential role of recombinant hematopoietic colony-stimulating factors in preventing infections in the immunocompromised hostEmerging agents for the prevention of treatment induced neutropenia in adult cancer patients.Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerPegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.Exogenous endothelial cells as accelerators of hematopoietic reconstitution.Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin.Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia.The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis.Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.New G-CSF agonists for neutropenia therapy.G-CSF: filgrastim, lenograstim and biosimilars.Hemopoietic stem cells: stochastic differentiation and humoral control of proliferation.Future prospects for the therapy of multiple myeloma.Impact of Abbreviated Filgrastim Schedule on Survival and Hematopoietic Recovery after Irradiation in Four Mouse Strains with Different Radiosensitivity.Challenges in detecting substances for equine anti-doping.Colony-stimulating factors in the pathogenesis and treatment of disease.
P2860
Q24599936-BE6D1F70-5E22-4CEA-AB81-1E8DA0257626Q26738509-7A8C6144-1468-42FE-87E3-D4D029D736CEQ26825518-48A0DB22-05FD-4B70-8139-7FF4840739E0Q33372274-ECFE5A80-F596-46DF-B3A8-D60C796B9E8FQ33559130-2272C322-3621-4731-8E41-9E968639D481Q33574010-3FE7B5DB-82D0-40F6-A1F8-26397FC377CBQ33618882-A11346DC-6C77-4330-960E-562BACBDA1C4Q33780538-CFFFFB9D-264A-41A9-A47E-D8C806BFEC74Q33919728-04235F75-EDE1-4236-ACF4-2CF5859AEDD2Q33941431-3D3147C7-A981-4414-9CCA-12FF8FFCAD7CQ34013208-21782C0C-D4AD-4560-8AD8-BA63E931630BQ34077184-6DD29D16-5E9B-42F5-8539-97793FF02F25Q34251111-1BED0BBC-EE73-42A6-BF4D-C23363C0CF22Q34323778-4607170B-0D8F-4364-BF0A-740B1D0B3CB9Q34353198-5D924C7F-3806-4B16-90F4-609317C863CAQ34378498-3D1E1C08-F99A-4A22-B5F0-66F8A3AA82DCQ34578841-33CA3D0D-F984-44EE-9DF1-468204DD674AQ34628824-87DAA1E7-806C-4A24-9D65-3AE8D038814BQ35096749-AA867630-55DD-4310-B85E-560838B79797Q35298321-234F3465-99F1-48EF-AAB9-9DDB2236B781Q35337958-08F16E46-9668-43CE-96BF-8A12AC96CF4DQ35532901-0655BD00-876F-4DAD-95DE-C09F600A5F29Q35536280-D4D6EDB4-5638-4017-8284-4E1DD3C9161FQ35592216-5EA9B91A-5A28-46F6-86C4-E5F9D5A69BF9Q35893155-7B27FC4E-8D20-496F-B491-8FB0349A8AA9Q36007020-A58E6FAE-FE7D-46B9-9B65-58E79084DDD0Q36029532-11864940-2B56-4E6D-9336-D20DD66CD349Q36235531-5DC2DEE8-77EC-4277-8D79-FC27E87EF987Q36527110-F85FC708-5978-46F9-B8EC-823A532E7DA1Q36589367-31396961-0070-4068-9092-CF5DCD0DA4BFQ37354699-C935BF5E-58C1-4F4D-9498-C4DFD7E93357Q37777393-542F07E6-3BD3-4533-92A9-61BDEE198286Q38072290-BB478D5B-65CF-4E8B-8160-6FD7F232EA9DQ38145338-01B045F0-8216-48EC-B62F-CEF5B85505E7Q38202661-C40E9BBA-D352-40E9-9C6F-1ED8F367AFA2Q38609283-310A87A6-0430-4F55-B8E2-081D64B0C3BDQ38694720-14997A1D-74E2-43AF-8379-4092580F76A9Q38865036-9E47492F-9DD0-40CA-8F4C-5370CCB66353Q39088561-13FAE1CB-41A7-40D4-8711-9195991039E8Q39177018-1F3D5A34-FFB1-4174-AF59-78C755E9404E
P2860
Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Recombinant human granulocyte ...... ophosphamide-treated primates.
@ast
Recombinant human granulocyte ...... ophosphamide-treated primates.
@en
type
label
Recombinant human granulocyte ...... ophosphamide-treated primates.
@ast
Recombinant human granulocyte ...... ophosphamide-treated primates.
@en
prefLabel
Recombinant human granulocyte ...... ophosphamide-treated primates.
@ast
Recombinant human granulocyte ...... ophosphamide-treated primates.
@en
P2093
P2860
P356
P1476
Recombinant human granulocyte ...... ophosphamide-treated primates.
@en
P2093
A P Gillio
G K Potter
J L Gabrilove
M A Bonilla
R J O'Reilly
P2860
P304
P356
10.1084/JEM.165.4.941
P407
P577
1987-04-01T00:00:00Z